Develops therapies that aim to restore regulatory T-cell function, including biologic combinations, for people with neurodegenerative, autoimmune and metabolic diseases.
10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells…View ↗
Our core focus is developing therapies to target Treg dysfunction. Treg dysfunction has been identified as an important pathophysiological…View ↗
Our strategy is to discover, develop, manufacture, and commercialize proprietary medicinal products that enhance the function of Tregs. We…View ↗
Dr. Reddy’s pays Coya under a development and license agreement through upfront license fees, regulatory or commercial milestone payments, and royalties on licensed-product sales. Coya also earns collaboration revenue for research and development services as that work progresses.
10-K for FY2025, filed Mar 16, 2026 8-K, filed Nov 10, 2026The Company’s revenues have been solely generated through the DRL Development Agreement (Note 10), which falls under the scope of ASC Topic…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone Payments: At the inception of an agreement that includes regulatory or commercial milestone payments, the Company evaluates…View ↗
Royalties: If the Company is entitled to receive sales-based royalties from its collaborator, including milestone payments based on the…View ↗
R&D Services revenue is calculated quarterly using the inputs approach, by applying actual COYA 302 - ALS expenses against budgeted COYA…View ↗
$7.9M
10-K for FY2025, filed Mar 16, 2026
$7.9M ↗
Dr. Reddy’s works with Coya under a development and license agreement for COYA 302; the arrangement also covers Coya’s research and development services.
10-K for FY2025, filed Mar 16, 2026 8-K, filed May 12, 2026Collaboration revenue was $0.3 million for each of the three months ended March 31, 2026 and 2025, and related to the Company’s R&D…View ↗
No. It lost $21.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$10.6MView ↗
8-K, filed Apr 2, 2026
On March 29, 2026, Dr. Howard Berman resigned from the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) and from…View ↗
From parallel programs to a clinical focus
The older report described advancing multiple therapeutic approaches and candidates in parallel. The latest report centers clinical work on its biologic combination for ALS and FTD, while seeking outside support for another candidate and continuing early exosome research.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 16, 2026Our business strategy is to advance our multiple therapeutic modalities and product candidates simultaneously, which we believe sets the…View ↗
Advance the development of COYA 302 (A Pipeline within a Product). Our principal strategic goal is to advance COYA 302 for ALS and COYA 302…View ↗
Develop COYA 303 for AD and other neurodegenerative diseases. We intend to seek business development opportunities and/or grants to advance…View ↗
Leverage in-licensed technology to advance exosomes as potential therapies. Continue to pursue scientific and preclinical validation of…View ↗
Competes with Ionis Pharmaceuticals, Neurizon Therapeutics, Alchemab Therapeutics, Athira Pharma, NeuroSense Therapeutics, Amylyx Pharmaceuticals, Medicinova, Clene Nanomedicine, Amgen, Nektar Therapeutics, Merck, Xencor, Cue Biopharma, Moderna, ILTOO Pharma, Abata Therapeutics, Sonoma Biotherapeutics, Sangamo Therapeutics, TRex Bio, and Mozart Therapeutics
10-K for FY2025, filed Mar 16, 2026Clinical-stage competitor companies developing drugs for ALS include: Ionis Pharmaceuticals (in collaboration with Biogen), Neurizon…View ↗
Loading...